Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Rocapuldencel-T (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics
- 15 Sep 2017 Planned End Date changed from 18 Jul 2019 to 1 Sep 2017.
- 15 Sep 2017 Planned primary completion date changed from 14 Jul 2018 to 1 Sep 2017.
- 15 Sep 2017 Status changed from recruiting to withdrawn prior to enrolment.